Payment overview · 2025
General Payments
$103.88
4 reported records · 2 companies
Healthcare provider profile · identity verified
Sherell Denise Vicks, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LITHONIA, GA · NPI 1932251253
Verified facts
What the public records show
CMS Open Payments records show Sherell Denise Vicks, M.D. received $103.88 in general payments during 2025 across 4 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 81.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $84.22 | 81.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.66 | 18.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $103.88 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $84.22 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 546 | 152 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 232 | 75 |
| Atorvastatin Calcium | Atorvastatin Calcium | 213 | 64 |
| Losartan Potassium | Losartan Potassium | 203 | 55 |
| Montelukast Sodium | Montelukast Sodium | 182 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 175 | 47 |
| Desloratadine | Desloratadine | 172 | 77 |
| Gabapentin | Gabapentin | 124 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 120 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 112 | 41 |
| Lisinopril | Lisinopril | 112 | 31 |
| Metformin Hcl | Metformin Hcl | 111 | 36 |
| Simvastatin | Simvastatin | 96 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 95 | 30 |
| Azithromycin | Azithromycin | 88 | 68 |
| Meloxicam | Meloxicam | 86 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 25 |
| Tramadol Hcl | Tramadol Hcl | 83 | 21 |
| Furosemide | Furosemide | 78 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 40 |
| Allopurinol | Allopurinol | 76 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 22 |
| Nifedipine Er | Nifedipine | 72 | 23 |
| Omeprazole | Omeprazole | 70 | 21 |
| Trulicity | Dulaglutide | 70 | suppressed |
| Glimepiride | Glimepiride | 69 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 68 | 16 |
| Famotidine | Famotidine | 67 | 24 |
| Mounjaro | Tirzepatide | 67 | 14 |
| Atenolol | Atenolol | 65 | 18 |
| Eliquis | Apixaban | 65 | 19 |
| Trazodone Hcl | Trazodone Hcl | 63 | 18 |
| Carvedilol | Carvedilol | 61 | 19 |
| Methylprednisolone | Methylprednisolone | 61 | 48 |
| Potassium Chloride | Potassium Chloride | 61 | 25 |
| Ezetimibe | Ezetimibe | 59 | 17 |
| Memantine Hcl Er | Memantine Hcl | 57 | 13 |
| Temazepam | Temazepam | 56 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 16 |
| Ozempic | Semaglutide | 54 | 16 |
| Candesartan Cilexetil | Candesartan Cilexetil | 50 | 11 |
| Ibuprofen | Ibuprofen | 50 | 15 |
| Risedronate Sodium | Risedronate Sodium | 49 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 16 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 45 | 15 |
| Buspirone Hcl | Buspirone Hcl | 44 | 13 |
| Alendronate Sodium | Alendronate Sodium | 43 | 12 |
| Telmisartan | Telmisartan | 43 | 11 |
| Azelastine Hcl | Azelastine Hcl | 41 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 39 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 21 |
| Sertraline Hcl | Sertraline Hcl | 37 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | 17 |
| Meclizine Hcl | Meclizine Hcl | 35 | 16 |
| Clonidine | Clonidine | 34 | suppressed |
| Glipizide | Glipizide | 33 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 24 |
| Methimazole | Methimazole | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 31 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Repaglinide | Repaglinide | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Prednisone | Prednisone | 29 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Colchicine | Colchicine | 25 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 22 |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 18 |
| Linzess | Linaclotide | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 11 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Spironolactone | Spironolactone | 13 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $103.88 · 4 records | Otsuka America Pharmaceutical, Inc. | Ozempic, REXULTI, Rybelsus | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error